SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: yosi s who wrote (714)4/22/1999 10:12:00 PM
From: tommysdad  Read Replies (1) | Respond to of 1386
 
I assume you mean tamoxifen.

The problem, of course, is that everyone has a "tamoxifen analog". Pfizer, AHP, Lilly, etc. etc. DRMD is even taking generic tamoxifen forward. PARS seems a little late to the game. Who would they partner with? Every big Pharma already has their own program . . .



To: yosi s who wrote (714)4/23/1999 9:51:00 AM
From: Ron  Respond to of 1386
 
YOSI...thank you for the reply.



To: yosi s who wrote (714)4/23/1999 10:39:00 AM
From: arnie h  Read Replies (2) | Respond to of 1386
 
Yosi: I'm sure you didn't mean to imply to Ron that approval for
Pars 'Tamoxiphen' is likely at this point. Ron may not realize the road from pre-phase 1 to FDA approval is filled with many pitfalls and most candidates don't make it. Still Pars's candidate is an interesting speculation.

Regards,
Arnie H


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News